Plastic container
A plastic container has superior storage stability for pharmaceutical ingredients exhibiting a high affinity to plastic and can be mass-produced at low cost. The container has a bag body formed into a bag shape by a sheet member with a storage part on the inside thereof, and a tubular port member attached to the bag body, wherein one end of the tubular port member communicates with the storage part and an opening part of the other end is exposed outside of the bag body. The sheet member is formed from two or more layers including a base resin layer and an innermost layer formed from an amorphous polymer, as a main component, formed by polymerizing at least one type of olefin monomer, having a cyclic hydrocarbon skeleton, and the port member is formed from a resin having a crystalline polyolefin having no cyclic hydrocarbon skeleton, as a main component.
1. A plastic container comprising: a bag body which is formed into a bag shape by a sheet member and has a storage part on the inside thereof; and at least one tubular port member attached to said bag body, in which one end of the tubular port member communicates with the storage part and an opening part of the other end is exposed outside of the bag body,
wherein said sheet member is formed from two or more layers including a base resin layer and an innermost layer, and said innermost layer is formed from an amorphous polymer, as a main component, formed by polymerizing at least one type or two or more types of olefin monomers, in which at least one type of said olefin monomers is a monomer having a cyclic hydrocarbon skeleton,
wherein said port member is formed from a resin having a crystalline polyolefin having no cyclic hydrocarbon skeleton, as a main component; and
wherein a relationship between a total content contact area S B (cm 2 ) of said bag body and a total content contact area S P (cm 2 ) of said port member satisfies the following (Expression 1):
0.01 ≤S P /S B ≤0.15 (Expression 1).
2. The plastic container according to claim 1 , wherein said crystalline polyolefin is selected from one or more types of polyethylene, polypropylene, and ethylene/alpha-olefin copolymer.
3. The plastic container according to claim 1 , wherein said amorphous polymer has a glass transition temperature of 70° C. or higher.
4. The plastic container according to claim 1 , wherein the amorphous polymer has a glass transition temperature of 100° C. or higher.
5. The plastic container according to claim 1 , wherein said plastic container is in the form of an infusion bag or a blow molded container.
6. The plastic container according to claim 1 , wherein contents stored in said plastic container is a pharmaceutical product.
7. The plastic container according to claim 6 , wherein said pharmaceutical product is an aqueous solution containing a pyrazolone derivative or a pharmaceutically acceptable salt thereof.
8. The plastic container according to claim 7 , wherein said pyrazolone derivative is 3-methyl-1-phenyl-2-pyrazolin-5-one.
9. The plastic container according to claim 1 , wherein the resin having the crystalline polyolefin having no cyclic hydrocarbon skeleton further includes a styrene-based elastomer.
10. The plastic container according to claim 1 , wherein the port member has a dimension wherein an outer diameter is 4 to 20 mm, a wall thickness is 0.5 to 3 mm, and a length is 20 to 50 mm.
11. The plastic container according to claim 1 , wherein the innermost layer of the sheet member is formed from a cycloolefin polymer or cycloolefin copolymer.
12. The plastic container according to claim 1 , wherein the amorphous polymer has a glass transition temperature of 130° C. or higher.
13. The plastic container according to claim 1 , wherein a thickness of the sheet member is in a range from 70 to 400 μm, and a thickness of the innermost layer is in a range from 10 to 100 μm.
14. The plastic container according to claim 1 , wherein the plastic container is a flexible container which is a soft bag.
15. The plastic container according to claim 1 , wherein the plastic container is in the form of a syringe, ampoule or vial.
16. The plastic container according to claim 1 , wherein the port member and the innermost layer of the sheet member are welded.
17. The plastic container according to claim 6 , wherein the pharmaceutical product includes at least one selected from water and a pharmaceutical solution.
18. The plastic container according to claim 6 , wherein a relationship between a volume V (cm 3 ) of the contents stored in the plastic container and a content contact portion area of the plastic container, which is represented by S P +S B (cm 2 ), satisfies the following (Expression 2):
0.1< V /( S P +S B )<0.7 (Expression 2).